Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by SizzlinSteakson Mar 20, 2018 11:16pm

162 Views

Post# 27751021

RE:RE:Tommorows price

Difficult to predict the day to day trading but I'm certain this is just the beginning and we can all agree longer term this is going way up.

I remember can't remember the name of the stock but I remember it had massive news and nearly doubled every day for 5 days in a row. ATE may not do that but it sure does have the potential.

youngpupper wrote:

LARRY57 wrote: Open at.70 close at .75. ..just my prediction. What does anybody else think might happen

We're going after the ATH tomorrow, for sure.